NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company") (NASDAQ: MAPP) (ISIN: US56509R1086) (CUSIP: 56509R108) concerning the proposed acquisition of MAP Pharmaceuticals by Allergan, Inc. in a transaction valued at approximately $985 million in cash.
The investigation concerns whether the MAP Pharmaceuticals directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, MAP Pharmaceuticals shareholders will be entitled to receive $25.00 per share in cash for each share of MAP Pharmaceuticals common stock. However, at least one analyst noted that the offered price undervalues MAP Pharmaceuticals' new migraine treatment drug Levadex.
MAP Pharmaceuticals shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at email@example.com or 212-661-1100 or 888-476-6529, ext. 237.
The firm is also investigating actions on behalf of shareholders for the following companies: Arbitron Inc., Net1 Ueps Technologies, Inc., Hi-Crush Partners LP, Intermec, Inc., SandRidge Energy, Inc., Abiomed, Inc., Universal Technical Institute, and Clearwire Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune Technologies Bioressources, Inc. Telanetix, Inc.
The Pomerantz Firm, with offices in New York, Chicago and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP